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ABSTRACT
Staphylococcus aureus is a serious public health burden causing a wide variety of infections. Earlier
detection of such infections could result in faster and more directed therapies that also prevent
resistance development. Human monoclonal antibodies (humAbs) are promising tools for diagnosis
and therapy owing to their relatively straightforward synthesis, long history of safe clinical use and
high target speciﬁcity. Here we show that the humAb 6D4, which was obtained from a random
screen of B-cells producing antibodies that bind to whole cells of S. aureus, targets the
staphylococcal complement inhibitor (SCIN). The epitope recognized by 6D4 was localized to
residues 26 to 36 in the N-terminus of SCIN, which overlap with the active site. Accordingly, 6D4 can
inhibit SCIN activity as demonstrated through the analysis of C3b deposition on S. aureus cells and
complement-induced lysis of rabbit erythrocytes. Importantly, while SCIN is generally regarded as a
secreted virulence factor, 6D4 allowed detection of strongly increased SCIN binding to S. aureus
cells upon exposure to human serum, relating to the known binding of SCIN to C3 convertases
deposited on the staphylococcal cell surface. Lastly, we show that labeling of humAb 6D4 with a
near-infrared ﬂuorophore allows one-step detection of SCIN-producing S. aureus cells. Together, our
ﬁndings show that the newly described humAb 6D4 speciﬁcally recognizes S. aureus SCIN, which






Staphylococcus aureus is a highly adaptable and danger-
ous Gram-positive bacterial pathogen that is asymptom-
atically carried by about one-third of the human
population. S. aureus can cause a wide variety of infec-
tions due to its extensive arsenal of virulence factors.1 A
subset of these virulence factors target the human
immune system by blocking chemotaxis of phagocytes,
complement activation, oxidative killing or phagocytic
uptake. Alternatively, they may redirect host defenses,
such as ﬁbrin formation or formation of neutrophil
extracellular traps to favor pathogen replication.2 Thus,
the response of S. aureus to the human immune system
is highly ﬂexible, allowing survival in the host’s hostile
environment.3 Due to its adaptability S. aureus has also
become resistant to a broad spectrum of antibiotics,4 and
nowadays the drug-resistant lineages of S. aureus repre-
sent a serious public health burden.2,5 This applies in
particular to methicillin-resistant S. aureus (MRSA),
which causes signiﬁcantly increased morbidity and mor-
tality worldwide.6,7 Vancomycin has been the drug of
choice to treat MRSA infections, but strains have
emerged that display reduced vancomycin susceptibil-
ity.8 This implies that there is an urgent need for new
and reliable approaches to prevent and treat infections
by drug-resistant staphylococci.
Immune therapies against S. aureus infections have
been explored as a treatment alternative to antibiotics.
While active immunization could potentially prevent the
onset of S. aureus infections, passive immunization could
be applied to treat acute or current infections. While the
use of pooled human sera does not seem to be very effec-
tive,9,10 passive immunization with monoclonal antibod-
ies, preferably human monoclonal antibodies (humAbs),
is an attractive alternative option. Importantly, humAbs
have a high speciﬁcity, their synthesis is relatively
straightforward, and they have a long history of safe
use.11,12 However, despite recent successes in animal
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models,13-15 the efﬁcacy of passive immunization with
humAbs has not yet been conﬁrmed in clinical trials.11
Wounds of patients with the genetic blistering disease
epidermolysis bullosa (EB) are highly susceptible to bac-
terial colonization.16 In a study by van der Kooi-Pol
et al., it was documented that essentially all investigated
EB patients with chronic wounds were heavily colonized
with S. aureus.17 Interestingly, it was noted that these
patients did not frequently suffer from S. aureus bacter-
aemia, despite the impaired barrier function of the skin.
Compared to healthy individuals, the plasma of EB
patients contained signiﬁcantly higher IgG1 and IgG4
levels, suggesting a potentially protective effect of anti-
staphylococcal antibodies against invasive staphylococcal
infections.18,19 In a recent project, we therefore collected
B-cells from donors with EB and applied them to
develop of a set of fully human monoclonal antibodies
against molecules exposed on the cell surface of S.
aureus.13-15 The present study was aimed at the charac-
terization of one of these humAbs referred to as 6D4. In
brief, our results show that the humAb 6D4 binds specif-
ically to the staphylococcal complement inhibitor
(SCIN), thereby inhibiting its activity. Furthermore,
using 6D4, we show that cell surface binding of SCIN is
enhanced in the presence of human serum.
Results
Identiﬁcation of a human monoclonal antibody
that targets the staphylococcal complement
inhibitor SCIN
The humAb 6D4 was identiﬁed from a random
screen of B-cells producing antibodies that bind to
whole cells of S. aureus. Consequently, the actual tar-
get of 6D4 was initially not known. To identify the
antigen recognized by 6D4, immunoprecipitation
experiments were performed. However, the subse-
quent Mass Spectrometric analysis of precipitated
proteins yielded no conclusive identiﬁcation of the
respective antigen (not shown). As an alternative
approach toward target identiﬁcation, we performed
a Western blotting analysis on cells and growth
medium fractions of different S. aureus isolates. As
expected, 6D4 bound to the immunoglobulin-binding
proteins Spa (also known as protein A) and Sbi
(Fig. 1A). In addition, 6D4 was found to bind a pro-
tein of 10–15 kDa that was present both in the cell
and growth medium fractions of S. aureus
NCTC8325, its derivative NCTC8325 (DspaDsbi) and
NCTC8325 (DpknB) (Fig. 1, A and B). The respective
signal was however absent from samples of S. aureus
NCTC8325 (DpknBDF13) (Fig. 1B) and S. aureus
SH1000 (not shown). The latter strains both lack the
phage 13 (F13).20 This suggested that the antigen
recognized by 6D4 was most likely an exported pro-
tein of 10–15 kDa encoded by F13. Indeed, F13 enc-
odes 2 proteins, SCIN (13 kDa) and the Chemotaxis
Inhibitory Protein of S. aureus (CHIPS; 17 kDa),
which are known to be exported from the cytoplasm
to the extracellular milieu.
To test whether 6D4 binds to SCIN or CHIPS, the
respective genes were cloned and expressed with a His-tag
in Lactococcus lactis strain PA1001. As shown by Western
blotting with anti His-tag antibodies both SCIN and
CHIPS were expressed and secreted by L. lactis upon
induction with nisin (Fig. 1C). Importantly, the humAb
6D4 was found to bind speciﬁcally to SCIN (Fig. 1D). We
considered this an important observation as SCIN is a
potent inhibitor of the human complement system.21-23
HumAb 6D4 binds to the active site of SCIN
To identify the speciﬁc SCIN epitope recognized by
6D4, we applied a set of previously constructed
Figure 1. Identiﬁcation of SCIN as target of humAb 6D4.
Western blot analysis using humAb 6D4 on proteins from
cell pellet (P) and growth medium fractions (supernatant; S)
of the S. aureus (Sa) strains NCTC8325 and NCTC8325
DspaDsbi (A), and the growth medium fractions of strains
NCTC8325 DpknB and NCTC8325 DpknB DF13 (B). Western
blot analysis of the growth medium fractions of L. lactis
pNG4210::scn or pNG4210::chips secreting the SCIN or CHIPS
proteins, respectively, using anti-His-tag antibodies (C), or
humAb 6D4 (D). Molecular weights (kDa) of marker proteins
are indicated next to panel A.
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Escherichia coli Rosetta gami strains expressing IPTG-
inducible His-tagged chimera of SCIN and its S.
aureus homolog OrfD.24 The structure of these chi-
mera is schematically represented in Fig. 2A, showing
the relative positions of the 3 a-helices (a1, a2, and
a3), the N- and C-termini, and the active site of
SCIN. Of note, the OrfD protein has no identiﬁed
biologic activity,24 and our humAb 6D4 does not
bind to the full-size OrfD (Fig. 2D). All SCIN-OrfD
fusion proteins were expressed upon IPTG induction,
as shown by SDS-PAGE and Simply blue straining
(Fig. 2B) or by immunodetection with anti-His tag
antibodies (Fig. 2C), and all detected fusion proteins
were of the expected size (Fig. 2, B and C). To assess
the binding of 6D4 to the different SCIN-OrfD chi-
mera, this humAb was labeled with the near-infrared
ﬂuorophore IRDye 800CW. In Western blotting anal-
yses, the resulting 6D4–800CW facilitated the direct
detection of SCIN at 800 nm equally well as the indi-
rect detection of bound 6D4 with a secondary IRDye
800CW-labeled antibody at 800 nm (results not
shown). As shown in Fig. 2D, bound to most SCIN-
OrfD chimera. However, the 6D4–800CW did not
bind the CH-a1-CA fusion, while the CH-a1-C and
CH-a1-CB fusions were barely bound (Fig. 2D).
These ﬁndings imply that the epitope recognized by
6D4 is located within the C-terminal half of the ﬁrst
a-helix of the SCIN protein, within amino acid resi-
dues 26 to 36. Importantly, these residues overlap
with the active site of the SCIN protein.24
HumAb 6D4 speciﬁcally binds the S. aureus
SCIN protein
To verify the speciﬁcity of 6D4 for S. aureus, we per-
formed a BLAST analysis using the NCBI protein database
to identify other bacteria containing SCIN-encoding genes.
This showed that the presence of SCIN was restricted to S.
aureus, and that proteins with limited sequence similarity
to SCIN were encoded by the genomes of only few other
Staphylococcus species, including S. argenteus (61% iden-
tity from 89% query cover, GenBank: CDR22445.1), S.
hominis (53% identity from 73% query cover, GenBank:
EEK11996.1) and S. haemolyticus (57% identity from 74%
query cover, GenBank: CPM70056.1). In none of these
SCIN homologues was the epitope recognized by 6D4 (i.e.
residues 26 to 36) fully conserved. This was conﬁrmed by
Western blotting analyses, where 6D4–800CW showed no
binding to proteins from S. hominis or S. haemolyticus,
while clear binding to the SCIN proteins of different
sequenced S. aureus strains was detected (Fig. 3A). Of
note, our BLAST analysis indicated that S. aureus COL
does not contain the scn gene encoding SCIN and, consis-
tent with this ﬁnding, 6D4–800CW did not bind to any
protein of S. aureus COL (Fig. 3A).
SCIN is detectable in most clinical S. aureus isolates
To explore the production of SCIN by clinical isolates of
S. aureus, this was assessed with 6D4–800CW in a set of
24 clinical S. aureus isolates from the University Medical
Center Groningen of which 22 were previously shown by
PCR to carry the scn gene.25 Intriguingly, Western blot-
ting with 6D4–800CW revealed the presence of SCIN in
23 of the 24 tested isolates (Fig. 3B), including isolate G
which had tested negative for scn in the previous PCR
analysis. In contrast, isolate T which had also tested neg-
ative for scn in the previous PCR also tested negative in
the Western blotting with 6D4–800CW. A renewed PCR
using scn-speciﬁc primers showed that the scn gene was
indeed present in isolate G (data not shown), which is
Figure 2. HumAb 6D4 binds to the C-terminal part of the ﬁrst
a-helix of SCIN. Proteins from E. coli Rosetta Gami expressing
SCIN-OrfD chimera were separated using SDS-PAGE. The
expressed chimera of SCIN and OrfD are schematically presented
(A). The 3 helices (a1, a2 and a3) and the active site region of
SCIN (in gray shading) are indicated. SCIN residues (gray) were
exchanged with corresponding residues from OrfD (black).
Exchanged residues (in parentheses) are: CH-N (1–13), CH-C (83–
85), CH-a1N (1–25), CH-a1C (26–36), CH-a2N (37–48), CH-a2C
(49–58), CH-a3N (59–72), CH-a3C (73–86), CH-a1CA (26–30), CH-
a1CB (31–36), CH-a2NA (37–42), and CH-a2NB (43–48). Gels were
stained with simply blue to verify protein production (B), and the
produced proteins were speciﬁcally detected by immunoblotting
with an anti-His-antibody (C) or the humAb 6D4–800CW (D). The
positions of molecular weight marker proteins (kDa) are shown
next to the gel and Western blot images.
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consistent with the detection of SCIN with 6D4–800CW
in this isolate. Altogether, these results show that humAb
6D4 labeled with IRDye 800CW can be applied for the
speciﬁc identiﬁcation of clinical S. aureus isolates
expressing SCIN.
Serum incubation increases binding of SCIN
to S. aureus cells
The S. aureus SCIN protein speciﬁcally inhibits the
human complement system, one of the most important
components of the innate immune system.24,26-29 This is
achieved through the binding of SCIN to the C3b moiety
of human C3 convertases on the bacterial surface, lead-
ing to their stabilization in a catalytically inactive form
and preventing enhanced conversion of C3 into C3b as
part of the so-called ‘alternative pathway’ in innate
immunity. In addition, SCIN promotes the formation of
inactive convertase dimers that preclude C3b binding by
the complement receptor of phagocytic cells.27,30 Because
the C3 convertases are key initiators in the complement
activation cascades, effector functions such as C3b-medi-
ated phagocytosis and C5a-mediated cell recruitment are
effectively prevented by SCIN.21,23,24,27-30
From the Western blotting analyses shown in Figs. 1
and 3, it was evident that SCIN is mostly detectable in
growth medium fractions, and only to minor extent in
the cell fractions when cells are grown in Tryptic Soy
Broth (TSB). The latter is consistent with the previously
documented ﬁnding that SCIN binds to the C3 conver-
tases, which are formed on the S. aureus cell wall after
initial C3b deposition.26 Therefore, we hypothesized that
SCIN is likely more abundant in the cell fraction when
cell wall-attached C3b is present. To verify this idea, S.
aureus Newman DspaDsbi cells were covered with C3b
through incubation in human sera and, subsequently,
these cells were incubated in the presence or absence of
added SCIN. As reﬂected by 6D4–800CW binding upon
Western blotting, cells not incubated in serum displayed
low levels of SCIN, whereas the respective supernatant
fractions yielded a high signal due to the presence of
SCIN (Fig. 4). Similarly, the serum-incubated samples
without added SCIN showed a low signal in both the
cell- and the respective supernatant fractions. In con-
trast, the serum-incubated samples with added SCIN
showed a high SCIN-speciﬁc signal in the cell fraction
and a lowered signal in the supernatant fraction (Fig. 4).
These results show that the enhanced SCIN binding to
the S. aureus cell wall due to the deposition of C3b and
C3 convertases is readily detectable with the 6D4–
800CW humAb.
Figure 3. Binding of the humAb 6D4 to SCIN produced by different laboratory strains and clinical isolates of S. aureus. Western blotting
analysis using humAb 6D4–800CW to detect SCIN in the cell pellet (P) or growth medium (S) fractions of S. hominis, S. haemolyticus and
the S. aureus strains Newman, USA300, Mu50, MW2, N315, COL, NCTC8325–4, MRSA252 and MSSA476 (A), or in the growth medium
fractions (supernatant) of 24 clinical S. aureus isolates named A-J and L-Y (B). Molecular weights (kDa) of marker proteins are indicated
to the left of panels A and B. Loading of comparable amounts of proteins was conﬁrmed by Simply Blue staining (not shown).
Figure 4. Binding of SCIN to S. aureus cells increases upon incu-
bation in serum. Western blotting analysis of S. aureus Newman
DspaDsbi cells collected by centrifugation (P) and growth
medium fractions (S) using 6D4–800CW. The presence or absence
of C3 convertases due to serum incubation, and the addition or
absence of SCIN are indicated with C or -, respectively.
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A plate assay was used to assess whether whole S.
aureus cells could be detected after incubation with
human sera using 6D4–800CW. Indeed, 6D4–800CW
was found to bind concentration-dependently to the
S. aureus clinical isolate P, and the strains USA300,
Newman wild-type and Newman DspaDsbi (Fig. 5A).
In this assay binding of 6D4 to Spa and Sbi via the
Fc-region was blocked by the addition of unrelated
rabbit IgG, and effective blocking was conﬁrmed with
a control His-tag-speciﬁc rabbit antibody (a-his-tag;
Fig. 5A). Importantly, 6D4–800CW allowed the detec-
tion of cell-bound SCIN in 19 of 24 clinical S. aureus
isolates tested (Fig. 5B) Here it is noteworthy that 5
isolates showed no enhanced binding of SCIN,
including 4 scn-proﬁcient isolates and the isolate T
lacking the scn gene. Furthermore, 6D4–800CW
allowed detection of cell-bound SCIN for 8 of 9
sequenced S. aureus strains, where only the COL
strain that lacks the scn gene yielded no signal
(Fig. 5B). Binding of the a-his-tag control antibody
was low for all strains due to blocking with an unre-
lated rabbit IgG (Fig. 5B).
Direct detection of SCIN bound to the surface of
S. aureus cells
For direct detection of SCIN bound to the surface of
S. aureus cells, samples of S. aureus Newman
DspaDsbi were prepared and spotted onto glass slides
for ﬂuorescence microscopy at 800 nm. S. aureus
cells grown under standard culturing conditions and
incubated with 6D4–800CW displayed almost no
ﬂuorescence and individual cells could not be distin-
guished (Fig. 6, A and B). Further, cells incubated in
Figure 5. Binding of the humAb 6D4 to whole cells of S. aureus. Plates were coated with whole cells of various S. aureus clinical isolates
or laboratory strains harvested from cultures in the mid-exponential growth phase where the growth medium was supplemented with
human serum. 6D4–800CW was used for the detection of cell-bound SCIN, and an a-his-tag antibody was used as a negative control.
Fluorescence readings at 800 nm are plotted relative to the binding of 6D4–800CW to S. aureus Newman DspaDsbi. All measurements
were performed in triplicate and the mean § standard error (error bars) is shown. (A) concentration-dependent binding of 6D4–800CW
to S. aureus Newman DspaDsbi, Newman wild-type (wt), the clinical S. aureus isolate P, or the MRSA strain USA300 is indicated in in
black symbols; the lack of binding of the a-his-tag control antibody to S. aureus Newman DspaDsbi, Newman wild-type (wt), isolate P,
or USA300 is shown in gray symbols. (B) Binding of 6D4–800CW to S. aureus Newman DspaDsbi, various clinical S. aureus isolates and
the sequenced S. aureus strains USA300, Mu50, MW2, N315, COL, 8325–4, MRSA252, MSSA476, Newman wild-type (WT) and Newman
DspaDsbi is indicated with black bars; binding of 100 ng/mL isotype control antibody IQNPA to the S. aureus clinical isolates and
sequenced S. aureus strains as speciﬁed is indicated with white bars.
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serum, but lacking added SCIN, showed no ﬂuores-
cent signal at all (Fig. 6, C and D). Importantly how-
ever, serum-incubated cells with added SCIN showed
a strongly enhanced ﬂuorescent signal at 800 nm
(Fig. 6, E and F). Here individual cells were detect-
able, though it is noteworthy that not all cells
appeared to be ﬂuorescently tagged. Taken together,
these observations show that S. aureus cells incubated
with human serum have a high potency for binding
of SCIN, most likely due to the deposition of C3b
and C3 convertases, which can be detected with
IRDye 800CW-labeled 6D4 humAb.
Impact of 6D4 on SCIN activity
Since the humAb 6D4 binds to the active site of
SCIN, we asked the question how this antibody
impacts on the deposition of C3b on the S. aureus
cell surface. To this end, we used an essay where
increasing amounts of SCIN were pretreated with
6D4, before mixing with human serum. As controls,
the SCIN protein was mock-treated with buffer or a
control IgG before mixing with serum. Next, S.
aureus Newman DspaDsbi cells were incubated for
30 min with the serum containing SCIN (with or
without 6D4 pretreatment), after which the presence
of C3b on the staphylococcal cell surface was mea-
sured by ﬂow cytometry. As shown in Fig. 7A, in
this assay the preincubation of SCIN with humAb
6D4 resulted in a relative deposition of C3b on the S.
aureus cells close to 1, which represents the maximal
C3b deposition upon incubation with serum. In con-
trast, the C3b deposition was inhibited by SCIN in
the absence of 6D4. These ﬁndings imply that 6D4
Figure 6. Serum-incubated S. aureus cells display elevated levels of SCIN binding. Phase contrast (panels A, C, E) and subsequent ﬂuores-
cence microscopy at 800 nm (panels B, D, F) of cells of S. aureus Newman DspaDsbi collected from an overnight culture. Speciﬁcally, the
panels show cells from the overnight culture (A, B), cells treated with serum but without the addition of SCIN (C, D), and cells treated
with serum and added SCIN (E, F). Cell-bound SCIN was detected using 6D4–800CW.
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can interfere with the deposition of C3b on the S.
aureus cells.
An alternative possibility to measure the impact of 6D4
on SCIN activity is provided by the fact that complement
causes the lysis of rabbit erythrocytes, and that this hemo-
lysis can be inhibited by SCIN. To assess whether SCIN-
mediated inhibition of the alternative pathway’s hemolytic
activity can be suppressed by 6D4, we pre-treated increas-
ing amounts of SCIN with 6D4, before mixing with
human serum and erythrocytes. As a negative control, the
SCIN protein was either mock-treated with buffer or a
control IgG before mixing with serum and erythrocytes.
Next, the erythrocytes were incubated for 60 min with the
human serum containing SCIN (with or without 6D4 pre-
treatment), after which the erythrocytes were pelleted and
the absorbance of supernatants at 450 nm was measured
to assess the erythrocyte lysis. As shown in Fig. 7B, the
preincubation of SCIN with 6D4 signiﬁcantly reduced the
protective effect of SCIN with respect to erythrocyte lysis,
as compared with SCIN preincubated with the control
IgG or with buffer. These observations fully support the
view that the activity of SCIN can be inhibited by the
humAb 6D4.
Discussion
In this study, we show that the humAb 6D4 binds to
the ﬁrst a-helix of the staphylococcal complement
inhibitor SCIN, which covers part of this protein’s
active site domain. Consistent with this ﬁnding, 6D4
interferes with the activity of SCIN, as shown through
the analysis of C3b deposition on S. aureus cells and
suppression of the protective effect of SCIN in the
alternative pathway-mediated hemolysis of rabbit
erythrocytes. Furthermore, we show that 6D4 labeled
with the near-infrared ﬂuorophore IRDye 800CW can
be readily used to visualize the production and sub-
cellular localization of SCIN by S. aureus.
The analysis of publicly available bacterial genome
sequences suggests that the scn gene is speciﬁc for S.
aureus isolates causing infections in humans. While
sequenced S. hominis and S. haemolyticus strains contain
genes with some sequence similarity to the S. aureus scn
gene, the tested S. hominis and S. haemolyticus strains
did not bind humAb 6D4. This underpins the conclusion
that this humAb is highly speciﬁc for S. aureus SCIN,
and suggests that it will bind preferentially to isolates
associated with infections in humans. Previous studies
have reported that SCIN may be present in 90% of all
clinical S. aureus isolates and that it is expressed in
vivo.21-24 Consistent with this view, we observed that,
from a panel of 33 tested S. aureus isolates, only 2 did
not express SCIN.
SCIN is a potent antigen that evokes high anti-
body titres in S. aureus-colonized individuals.18,31,32
Under the in vitro conditions used for culturing S.
aureus in this study, the clearest SCIN signals were
obtained for growth medium fractions, while the sig-
nals in the respective S. aureus cell fractions were rel-
atively low. On the other hand, our present ﬁndings
Figure 7. Impact of humAb 6D4 on SCIN activity. (A) C3b deposition on S. aureus Newman DspaDsbi cells upon preincubation of SCIN
with humAb 6D4 (■). C3b deposition was monitored by ﬂow cytometry. As a negative control, SCIN was preincubated with buffer (^),
or control IgG (~). Each data point represents the mean § standard error (error bars) of 3 independent experiments. (B) Reduced SCIN-
mediated protection of rabbit erythrocytes against lysis by complement upon incubation of SCIN with humAb 6D4 (■). Hemolysis was
quantiﬁed by pelleting of erythrocytes and subsequent measurement of the absorbance of supernatants at 450 nm. As a control, SCIN
was preincubated with buffer (^), or control IgG (~). Each data point represents the mean § standard error (error bars) of 2 separate
experiments.
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show that SCIN was effectively recruited to the
S. aureus cell surface when this bacterium was
exposed to human serum. This phenomenon was also
clearly evident at the single cell level by ﬂuorescence
microscopy. The observed redistribution of SCIN is
consistent with the fact that SCIN binds to the C3b
moiety of C3 convertases upon their deposition on
the bacterial cell surface.33 This puts emphasis on the
extensive interactions between S. aureus and its
human host, which are underestimated under the
generally applied in vitro culturing conditions. Indeed
this view is conﬁrmed by a previous study showing
that S. aureus cells bind a variety of human proteins
to their cell surface upon incubation in plasma.34 Of
note, when serum-incubated clinical S. aureus isolates
and laboratory strains were tested for enhanced bind-
ing of SCIN using 6D4–800CW, only 4 out of 34
investigated strains remained undetectable, which
suggests that they only bind small amounts of SCIN.
Notably, our Western blotting analyses show that
these strains produce relatively low amounts of
SCIN, which might not be sufﬁcient to distinguish
the SCIN-speciﬁc signal from the background signal
in a whole cell plate reader-based approach. Of note,
upon ﬂuorescence microscopy, not all S. aureus cells
appeared to bind equal amounts of 6D4–800CW,
suggesting that there may be cell-to-cell differences
in the formation of C3 convertases, the binding of
SCIN or the binding of 6D4–800CW.
In conclusion, in the present study we present a
humAb that binds to the active site of the S. aureus
SCIN protein, especially residues 26-36. While the
humAb 6D4 does interfere with the activity of SCIN,
it seems rather unlikely that it can be applied in anti-
staphylococcal therapy since SCIN-deﬁcient variants
of S. aureus can also cause infections. Importantly
however, the IRDye 800CW-labeled version of this
humAb (i.e., 6D4–800CW) can be applied to speciﬁ-
cally detect S. aureus isolates that express SCIN, an
important virulence factor that allows S. aureus to
effectively evade the human complement system. A
completely novel ﬁnding is that SCIN binding to the
staphylococcal cell-surface is substantially enhanced
in the presence of human serum. Since SCIN produc-
tion is associated in particular with S. aureus isolates
that caused infections in humans, our SCIN-speciﬁc
antibody may ﬁnd potential future applications in
the identiﬁcation of S. aureus lineages with a high
potential for causing infections. This could not only
involve diagnostic tests, but also in vivo imaging
approaches for which proof-of-principle was recently
obtained using vancomycin labeled with the IRDye
800CW.35-37
Materials and methods
Strains and growth conditions
Strains used in this study are listed in Table 1. E. coli
Rosetta Gami (DE3) pLysS strains (Novagen, Merck Bio-
sciences Darmstadt, Germany) carrying prSETB-derived
plasmids with the genes encoding for SCIN, OrfD or the
respective chimeric constructs have been described pre-
viously.24 E. coli Rosetta gami strains were grown over-
night in Lysogeny Broth (LB, Becton Dickinson, Breda,
The Netherlands) at 37C under vigorous agitation (250
rpm), in the presence of ampicillin (50 mg/ml) and chlor-
amphenicol (34 mg/ml) for plasmid selection. All staphy-
lococcal strains were cultured overnight in TSB (Oxoid
Limited, Hampshire, UK) at 37C under vigorous agita-
tion (250 rpm), unless otherwise speciﬁed. L. lactis
strains were grown at 30C in M17 broth (Oxoid Lim-
ited), or on plates containing 1.5% agar and 0.5% glucose
(wt/vol), supplemented with chloramphenicol (5 mg/ml)
for plasmid selection.
Sample preparation, SDS/LDS-PAGE, western
blotting and immunodetection
For the production of chimera of SCIN and the homolo-
gous OrfD protein of unknown function overnight cul-
tures of described previously E. coli Rosetta gami
strains24 were diluted to an optical density at 600nm
(OD600) of 0.1. Chimeric protein production was
induced at an OD600 of »0.5 by the addition of 1 mM
isopropyl-b-D-thiogalactopyranoside (IPTG). After 4 h
of continued cultivation, cells were collected by centrifu-
gation, and the SCIN-OrfD chimeras produced by these
cells were separated by SDS-PAGE as described previ-
ously.24 The replacement of SCIN residues with corre-
sponding OrfD residues is detailed in Fig. 2 and the
corresponding legend.
For the preparation of LDS-PAGE samples, S.
aureus cells collected by centrifugation were disrupted
with 0.1 mm glass beads (Biospec Products, Bartles-
ville, USA) in a Precellys 24 homogenizer (Bertin
Technologies, France), and resuspended in LDS sam-
ple buffer (Life Technologies). Growth medium frac-
tions were prepared for LDS-PAGE as described
before1 Proteins were separated on NuPAGE gels
(Life Technologies) and either visualized by Simply
Blue Safe Staining (Life Technologies)1 or Western
blotting using either mouse anti-His tag (Life Tech-
nologies), IRDye 800CW-labeled humAb 6D4, or
IRDye 800CW-labeled secondary goat anti-human or
goat anti-mouse antibodies (LI-COR Biosciences).
Bound antibodies were visualized using an Odyssey
Infrared Imaging System (LI-COR Biosciences).
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Expression of staphylococcal SCIN and CHIPS
proteins in L. lactis
Primers used for cloning are described in Table 2. DNA
ampliﬁcation was performed using Fusion Hot start
High-Fidelity DNA polymerase according the instruc-
tions of the supplier (Thermoscientiﬁc). Bacterial chro-
mosomal DNA was isolated using the ZR BAC DNA
Miniprep Kit (Zymo Reasearch Corporation, USA) fol-
lowing the manufacturer’s protocol. Primer pairs Scin-
up/Scin-low used for detection of scn, the gene encoding
SCIN, were used as described previously.25 Cloning of
the PCR-ampliﬁed scn and chp genes was performed by
Not1 and BamH1 (New England Biolabs) cleavage fol-
lowed by ligation to NotI/BamHI cleft plasmid
pNG4210.38 Ligated mixtures were used to transform
electrocompetent L. lactis PA1001 as described.39 All
constructs thus obtained were veriﬁed by sequencing
(Euroﬁns MWG Operon, Ebersberg, Germany).
The production of secreted SCIN and CHIPS in expo-
nentially growing (»0.5 OD600) cultures of L. lactis was
induced by the addition of nisin (3 ng/ml, Sigma-
Aldrich, St. Luis, MO). Growth medium fractions were
harvested after overnight incubation at 30C, and pro-
teins in these fractions were analyzed by LDS-PAGE,
Simply Blue Safe Staining, or Western blotting as
described above.
S. aureus incubation in human sera
Cells of S. aureus Newman DspaDsbi were collected
from the growth medium by centrifugation at
14.000 rpm for 2 min. The supernatant fraction, con-
taining secreted SCIN, was collected. Next, the collected
cells were resuspended and incubated with 20% human
serum in HBS (Hepes Buffered Saline; 20mM Hepes,
140 mM NaCl) plus 5 mM CaCl2 and 2.5 mM MgCl2
for 30 min to coat the bacteria with C3B and allow for
the formation of C3 convertases. Subsequently, the cells
were incubated in PBS at 37C for 30 min to dissociate
surface-bound C2a/Bb. Where appropriate, the col-
lected S. aureus supernatant was added to the C3 con-
vertase-covered bacteria to allow binding of SCIN to
the surface-attached C3 convertase. The protocol for
blood donations from healthy volunteers was approved
by the Independent Ethics Committee of the Founda-
tion ‘Evaluation of Ethics in Biomedical Research’
(Assen, the Netherlands). This protocol is registered by
QPS Groningen (code 04132-CS011). The required
written consent was obtained for all donors included in
the present studies.
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S. hominis Human commensal strain
obtained from UMCG
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(DE3) pLysS








pNG4210 CmR, containing PnisA, SSusp45,
BamHI/EcoRI-XbaI/NotI
cloning sites, and his6
38
pNG4210::scn pNG4210 containing scn with
C-terminal his6
This study
pNG4210::chp pNG4210 containing chp with
C-terminal his6
This study
prSETB::scn/orfD Vectors for expression of
chimeric SCIN/OrfD fusions
24
Notes. CmR, chloramphenicol resistance gene; PT7, IPTG inducible T7-promoter;
PnisA, nisin-inducible promoter; his6, 6x histidine tag; SSusp45, signal sequence
of usp45; MCS, multiple cloning site
Table 2. Primers used for detection or cloning of scn and chp genes.
Primer Sequence 50>30 Enzyme
Scn F ATATGGATCCACAAGCTTGCCAACATCGAATGAATATC BamHI
Scn R ATATGCGGCCGCATATTTACTTTTTAGTGCTTCGTCAATTTC NotI
Chp F ATATGGATCCTTTACTTTTGAACCGTTTCCTACAAATG BamHI
Chp R ATATGCGGCCGCGTATGCATATTCATTAGTTTTTC NotI
Scin-up AGTCTTTTGACTTAAGAGC
Scin-low GTTTTAGCATCACCACTAGTA
Notes., restriction enzyme sites are underlined in the nucleotide sequences.
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Detection of SCIN bound to whole cells of S. aureus
S. aureus isolates were grown overnight in TSB, diluted
1:100 in fresh medium and cultured until the mid-expo-
nential growth phase (OD600 »0.5). Next, the cells were
coated with complement by adding serum (end concen-
tration 20%) and incubation was continued for 30 min.
After this incubation, the bacteria were washed with
phosphate-buffered saline (PBS). High-binding ELISA
plates for ﬂuorescence measurements (Greiner Bio-one)
were coated with 5 £ 106 colony forming units (CFU)
per well in PBS for 18 h at 4C. Plates were blocked with
4% BSA in PBS with 0.05% Tween-20 (PBST). Surface-
bound IgG Fc-binding proteins of S. aureus (i.e., Spa and
Sbi) were saturated with 100 mg/mL normal rabbit
immunoglobulin fraction (DAKO) in PBST containing
1% BSA. The humAb 6D4 was labeled with IRDye
800CW (LI-COR Biosciences, Bad Homburg, Germany)
by incubation for 2 hours with 20 mg of IRDye 800CW
per mg of protein in PBS (pH 8.5). The mix was desalted
following the manufacturer’s instructions with a PD
minitrap G-25 desalting column (GE Healthcare, Ger-
many). The resulting 6D4–800CW was stored in the
dark at 4C. To quantify the binding of 6D4–800CW to
serum-incubated whole cells with added SCIN, the plates
were incubated with 300 ng/mL 6D4–800CW in PBS for
30 min, washed thrice with PBS and scanned with the
Odyssey infrared imaging system (Li-Cor Biosciences)
for ﬂuorescence at 800 nm.
Fluorescence microscopy
Overnight cultures in TSB were diluted to an OD600 of
10. Untreated samples were taken from the overnight
culture. Convertase-covered cell samples were obtained
as described above. Cells were collected by centrifugation
at 14.000 rpm for 2 min and washed with PBS. The
washed cells were incubated with the 6D4–800CW (3000
ng/mL in PBS) for 30 min. After the incubation, the cells
were collected by centrifugation at 14,000 rpm for 2 min
and washed with PBS. Next, cells were spotted on a glass
slide for microscopy, and a coverslip was mounted and
sealed. Fluorescence microscopy was performed using a
Leica DM5500B epiﬂuorescence microscope equipped
with an 800 nm ﬁlter block. Images were captured with a
Leica DFC365FX camera using a 63x objective (Leica
Microsystems BV, The Netherlands).
Determination of C3b deposition on S. aureus cells
Cells of S. aureus Newman DspaDsbi were collected as
described above, and 5£107 CFU/ml were incubated
with 5% pooled normal human serum in HBS plus
5 mM CaCl2, 2.5 mM MgCl2 and 0.1% human serum
albumin for 30 min at 37C while shaken at 700 rpm.
Different concentrations SCIN (0–4 mg/ml) were prein-
cubated with the puriﬁed humAb 6D4 (10 mg/ml), with
the control human anti-DNP IgG1 (10 mg/ml, Genmab,
Utrecht), or with HBS buffer for 10 min at room temper-
ature before mixing with the serum. Bacteria were
washed by centrifugation and incubated with 1 mg/ml
anti-C3b mAb (Quidel Corp.) for 30 min at 4C followed
by APC-labeled Goat-anti-Mouse-Ig (BD Biosciences).
Samples were ﬁxed with 1% paraformaldehyde
(Polysciences) and analyzed on a FACSVerse ﬂow
cytometer (BD Biosciences). Data are expressed relative
to the mean ﬂuorescence value of bacteria incubated in
serum only.23
The alternative pathway hemolytic assay
Washed rabbit erythrocytes at 1£108 c/ml (Biotrading)
were incubated with 5% pooled normal human serum in
HBS plus 10 mM MgCl2 and 10 mM EGTA for 60 min
at 37C while shaken at 600 rpm. Different concentra-
tions SCIN were preincubated with puriﬁed humAb 6D4
(10 mg/ml), with the control human anti-DNP IgG1
(10 mg/ml, Genmab, Utrecht), or with HBS-buffer plus
10 mM MgCl2 and 10 mM EGTA for 10 min at room
temperature before mixing with serum. Erythrocytes
were pelleted and the absorbance of supernatants at
450 nm was measured. Data are expressed relative to the
mean value measured for erythrocytes incubated with
serum only, which was set to 1.21
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